These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Giltay EJ; Haider A; Saad F; Gooren LJ Andrologia; 2008 Dec; 40(6):398-400. PubMed ID: 19032692 [TBL] [Abstract][Full Text] [Related]
65. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. Page ST; Amory JK; Bowman FD; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL J Clin Endocrinol Metab; 2005 Mar; 90(3):1502-10. PubMed ID: 15572415 [TBL] [Abstract][Full Text] [Related]
66. Could Testosterone Replacement Therapy in Hypogonadal Men Ameliorate Anemia, a Cardiovascular Risk Factor? An Observational, 54-Week Cumulative Registry Study. Zhang LT; Shin YS; Kim JY; Park JK J Urol; 2016 Apr; 195(4 Pt 1):1057-64. PubMed ID: 26519655 [TBL] [Abstract][Full Text] [Related]
67. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Saad F; Yassin A; Doros G; Haider A Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417 [TBL] [Abstract][Full Text] [Related]
68. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men. Canguven O; Talib RA; El Ansari W; Yassin DJ; Salman M; Al-Ansari A Andrologia; 2017 Dec; 49(10):. PubMed ID: 28295504 [TBL] [Abstract][Full Text] [Related]
69. Effects of testosterone supplementation in the aging male. Tenover JS J Clin Endocrinol Metab; 1992 Oct; 75(4):1092-8. PubMed ID: 1400877 [TBL] [Abstract][Full Text] [Related]
70. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Zitzmann M; Nieschlag E J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942 [TBL] [Abstract][Full Text] [Related]
71. [Low-dose testosterone undecanoate capsules combined with tadalafil for late-onset hypogonadism accompanied with ED]. Li GY; Liang JH; Meng ZB; Huang CC; Liang SK; Wei GQ; Shen SL; Zhu CH; Zhang X; Song WR Zhonghua Nan Ke Xue; 2013 Jul; 19(7):630-3. PubMed ID: 23926681 [TBL] [Abstract][Full Text] [Related]
72. Sleep disturbance as a clinical sign for severe hypogonadism: efficacy of testosterone replacement therapy on sleep disturbance among hypogonadal men without obstructive sleep apnea. Shigehara K; Konaka H; Sugimoto K; Nohara T; Izumi K; Kadono Y; Namiki M; Mizokami A Aging Male; 2018 Jun; 21(2):99-105. PubMed ID: 28920756 [TBL] [Abstract][Full Text] [Related]
73. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia. Krysiak R; Gilowski W; Okopien B Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507 [TBL] [Abstract][Full Text] [Related]
74. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870 [TBL] [Abstract][Full Text] [Related]
75. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. Kaminetsky JC; Moclair B; Hemani M; Sand M J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402 [TBL] [Abstract][Full Text] [Related]
76. 12-month observation of testosterone replacement effectiveness in a general population of men. Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767 [TBL] [Abstract][Full Text] [Related]
77. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. Raynaud JP; Gardette J; Rollet J; Legros JJ BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726 [TBL] [Abstract][Full Text] [Related]
78. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Mulhall JP; Valenzuela R; Aviv N; Parker M Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487 [TBL] [Abstract][Full Text] [Related]
79. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255 [TBL] [Abstract][Full Text] [Related]
80. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. von Eckardstein S; Nieschlag E J Androl; 2002; 23(3):419-25. PubMed ID: 12002444 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]